Design Therapeutics, Inc. Profile Avatar - Palmy Investing

Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia…

Biotechnology
US, Carlsbad [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of DSGN's Analysis
CIK: 1807120 CUSIP: 25056L103 ISIN: US25056L1035 LEI: - UEI: -
Secondary Listings
DSGN has no secondary listings inside our databases.